Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GridAI Technologies Corp.AZRX · Entity 7534 | Director · CHIEF FINANCIAL OFFICER | December 28, 2018 | January 02, 2019 |
| RELMADA THERAPEUTICS, INC.RLMD · Entity 5498 | Chief Financial Officer | September 09, 2026 | September 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GridAI Technologies Corp.
Report date December 28, 2018 · Filed January 02, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 62,500 |
Reported balance
After 2018-12-28 transaction · row 1
1 source rowRow 1 · 2018-12-28 · Purchase · Acquired 20,000 · Balance 62,500 |
RELMADA THERAPEUTICS, INC.
Report date September 09, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,000,000 |
Ending reported balance
After 2026-09-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-09 · Purchase · Acquired 120,200 · Balance 920,200 F1: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2: Purchase prices range from $4.16 to $4.20 per share, inclusive. Row 2 · 2026-09-10 · Purchase · Acquired 79,800 · Balance 1,000,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
F2: Purchase prices range from $4.16 to $4.20 per share, inclusive.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2026 Filed Sep 11, 2026 11:30 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 79,800 | $4.25 | $339,150.00 |
DisclosureSEC source: 0001213900-26-098970 · ownership.xml · nonDerivative · entry 2 Shenouda Maged · CIK 0001658369 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 11:30 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 120,200 | $4.20 | $504,840.00 |
DisclosureSEC source: 0001213900-26-098970 · ownership.xml · nonDerivative · entry 1 Shenouda Maged · CIK 0001658369 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 920,200 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · price: Purchase prices range from $4.16 to $4.20 per share, inclusive. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 09:30 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 11,665 | $4.12 | $48,059.80 |
DisclosureSEC source: 0001213900-25-121973 · ownership.xml · nonDerivative · entry 1 Shenouda Maged · CIK 0001658369 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800,000 Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 09:30 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Appreciation Rights · Derivative | 828,000 | $0.00 Strike: $4.06 | $0.00 |
DisclosureSEC source: 0001213900-25-121973 · ownership.xml · derivative · entry 2 Shenouda Maged · CIK 0001658369 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 828,000 Underlying: Common Stock · 828,000 shares Expires 2035-12-12 F1 · derivative.exercise_date: The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026. Read SEC document |
| November 05, 2025 Filed Nov 6, 2025 07:30 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 500,000 | $2.20 | $1,100,000.00 |
DisclosureSEC source: 0001213900-25-106836 · ownership.xml · nonDerivative · entry 1 Shenouda Maged · CIK 0001658369 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 788,335 Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 19:29 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001213900-25-059869 · ownership.xml · derivative · entry 1 Shenouda Maged · CIK 0001658369 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2035-06-26 F1 · derivative.exercise_date: The options vest in 16 equal quarterly installments commencing on September 26, 2025. Read SEC document |
| May 20, 2025 Filed May 20, 2025 18:03 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 60,000 | $0.52 | $31,422.00 |
DisclosureSEC source: 0001213900-25-046087 · ownership.xml · nonDerivative · entry 3 Shenouda Maged · CIK 0001658369 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 288,335 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F4 · price: Purchase prices range from $0.4998 to $0.5396 per share, inclusive. Read SEC document |
| May 19, 2025 Filed May 20, 2025 18:03 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 90,000 | $0.49 | $43,686.00 |
DisclosureSEC source: 0001213900-25-046087 · ownership.xml · nonDerivative · entry 2 Shenouda Maged · CIK 0001658369 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,335 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F3 · price: Purchase prices range from $0.4493 to $0.4998 per share, inclusive. Read SEC document |
| May 16, 2025 Filed May 20, 2025 18:03 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 50,000 | $0.44 | $22,100.00 |
DisclosureSEC source: 0001213900-25-046087 · ownership.xml · nonDerivative · entry 1 Shenouda Maged · CIK 0001658369 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,335 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · price: Purchase prices range from $0.4229 to $0.4674 per share, inclusive. Read SEC document |
| September 11, 2024 Filed Sep 11, 2024 17:46 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 24,120 | $2.95 | $71,154.00 |
DisclosureSEC source: 0001213900-24-077792 · ownership.xml · nonDerivative · entry 3 Shenouda Maged · CIK 0001658369 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,335 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F4 · price: Purchase prices range from $2.79 to $3.05 per share, inclusive. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 17:46 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 21,118 | $2.73 | $57,652.14 |
DisclosureSEC source: 0001213900-24-077792 · ownership.xml · nonDerivative · entry 2 Shenouda Maged · CIK 0001658369 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,215 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F3 · price: Purchase prices range from $2.70 to $2.75 per share, inclusive. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 17:46 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 8,194 | $2.55 | $20,894.70 |
DisclosureSEC source: 0001213900-24-077792 · ownership.xml · nonDerivative · entry 1 Shenouda Maged · CIK 0001658369 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,097 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · price: Purchase prices range from $2.49 to $2.60 per share, inclusive. Read SEC document |
| May 24, 2024 Filed May 29, 2024 21:24 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | OtherStock Option (right to buy) · Derivative | 54,624 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001213900-24-047638 · ownership.xml · derivative · entry 2 Shenouda Maged · CIK 0001658369 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,090 Underlying: Common Stock · 54,624 shares Expires 2033-12-15 F2 · kind: On May 24, 2024, the Reporting Person voluntarily forfeited to the Issuer a portion of the December Award equal to the Additional Award Shares so that those shares can be allocated to the holders of Similar Awards who are not executive officers or directors of the Issuer. Read SEC document |
| May 24, 2024 Filed May 29, 2024 21:24 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 54,624 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001213900-24-047638 · ownership.xml · derivative · entry 1 Shenouda Maged · CIK 0001658369 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,714 Underlying: Common Stock · 54,624 shares Expires 2033-12-15 F1 · kind: On May 24, 2024, under the terms of the option award granted to the Reporting Person on December 15, 2023 (the "December Award"), the Reporting Person became entitled to receive options for up to 54,624 additional shares of the Issuer's Common Stock on the same terms as the December Award (the "Additional Award Shares") out of shares that had become available under the terms of the Issuer's 2021 Equity Incentive Plan, as amended (the "Plan"), since December 15, 2023, as a result of expirations, cancelations, forfeitures and terminations of other outstanding awards under the Plan and/or tenders or withholding of shares. Read SEC document |
| January 31, 2024 Filed Jan 31, 2024 18:28 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 6,875 | $4.06 | $27,943.44 |
DisclosureSEC source: 0001213900-24-008559 · ownership.xml · nonDerivative · entry 3 Shenouda Maged · CIK 0001658369 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,903 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F4 · price: Purchase prices range from $3.95 to $4.18 per share, inclusive. Read SEC document |
| January 30, 2024 Filed Jan 31, 2024 18:28 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 15,000 | $3.89 | $58,323.00 |
DisclosureSEC source: 0001213900-24-008559 · ownership.xml · nonDerivative · entry 2 Shenouda Maged · CIK 0001658369 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,028 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F3 · price: Purchase prices range from $3.82 to $3.90 per share, inclusive. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 18:28 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 10,800 | $3.65 | $39,450.24 |
DisclosureSEC source: 0001213900-24-008559 · ownership.xml · nonDerivative · entry 1 Shenouda Maged · CIK 0001658369 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,028 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · price: Purchase prices range from $3.57 to $3.745 per share, inclusive. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 17:28 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 82,090 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001213900-23-097031 · ownership.xml · derivative · entry 1 Shenouda Maged · CIK 0001658369 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,090 Underlying: Common Stock · 82,090 shares Expires 2033-12-15 F1 · derivative.exercise_date: The options vest in 16 equal quarterly installments commencing on March 15, 2024. Read SEC document |
| May 25, 2023 Filed May 30, 2023 17:09 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 317,643 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0001213900-23-044089 · ownership.xml · derivative · entry 1 Shenouda Maged · CIK 0001658369 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 512,560 Underlying: Common Stock · 317,643 shares Expires 2032-12-16 F1 · date: The option grant was approved by the Board of Directors of the Company on December 16, 2022, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan, as amended (the "Plan"), increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2023, at the 2023 Annual Meeting of the Company's shareholders. F2 · derivative.exercise_date: 62,560 of the options immediately vested; 450,000 options vest in 16 equal quarterly installments commencing on March 16, 2023. F2 · balance_after: 62,560 of the options immediately vested; 450,000 options vest in 16 equal quarterly installments commencing on March 16, 2023. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 19:31 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | OtherStock Option (right to buy) · Derivative | 200,000 | Not disclosed Strike: $19.03 | Not disclosed |
DisclosureSEC source: 0001213900-22-081519 · ownership.xml · derivative · entry 1 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 200,000 shares Expires 2031-12-17 F1 · kind: Represents the termination of milestone-based stock options granted to the reporting person on May 25, 2022, that were eligible to vest based on achievement of certain corporate objectives by the Issuer. Upon grant, the target vesting amount was reported in Table II of Form 4. On December 16, 2022, the Board of Directors determined that such milestone objectives were not achieved by the Issuer and that all 200,000 options would be terminated. F1 · shares: Represents the termination of milestone-based stock options granted to the reporting person on May 25, 2022, that were eligible to vest based on achievement of certain corporate objectives by the Issuer. Upon grant, the target vesting amount was reported in Table II of Form 4. On December 16, 2022, the Board of Directors determined that such milestone objectives were not achieved by the Issuer and that all 200,000 options would be terminated. F2 · price: Not applicable. F2 · derivative.exercise_date: Not applicable. F3 · derivative.expiration_date: Original expiration date. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 17:34 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 194,917 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0001213900-22-081479 · ownership.xml · derivative · entry 1 Shenouda Maged · CIK 0001658369 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,917 Underlying: Common Stock · 194,917 shares Expires 2032-12-16 F1 · derivative.exercise_date: 62,560 of the shares are immediately vested; 132,357 shares vest in 16 equal quarterly installments commencing on March 16, 2023. Read SEC document |
| May 25, 2022 Filed May 26, 2022 18:42 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $19.03 | $0.00 |
DisclosureSEC source: 0001213900-22-029837 · ownership.xml · derivative · entry 2 Shenouda Maged · CIK 0001658369 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-12-17 F1 · date: The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the "Plan") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders. F3 · derivative.exercise_date: 50% of the option shall vest when the Board of Directors or Compensation Committee has determined that 301, 302 and 303 Trials of dextromethadone (REL-1017) in major depressive disorder ("MDD") complete enrollment, as defined in the respective Trial's protocol, with 364 patients per Trial with the last patient in for each trial to be enrolled by December 31, 2022. The remaining 50% of the option shall vest when the Board of Directors or Compensation Committee has determined that 301, 302 and 303 Trials of REL-1017 in MDD report top-line data by December 31, 2023, and meet or exceed their primary and key secondary endpoints as defined in in the respective Trial's protocol. Read SEC document |
| May 25, 2022 Filed May 26, 2022 18:42 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 295,211 | $0.00 Strike: $19.03 | $0.00 |
DisclosureSEC source: 0001213900-22-029837 · ownership.xml · derivative · entry 1 Shenouda Maged · CIK 0001658369 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 522,729 Underlying: Common Stock · 295,211 shares Expires 2031-12-17 F1 · date: The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the "Plan") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders. F2 · derivative.exercise_date: The option vests in 16 equal quarterly installments, at 6.25% per quarter, commencing on March 17, 2022. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 21:30 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 227,518 | $0.00 Strike: $19.03 | $0.00 |
DisclosureSEC source: 0001213900-21-066822 · ownership.xml · derivative · entry 1 Shenouda Maged · CIK 0001658369 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,518 Underlying: Common Stock · 227,518 shares Expires 2031-12-17 F1 · derivative.exercise_date: The option vests in 16 equal quarterly installments commencing on March 17, 2022. Read SEC document |
| March 10, 2021 Filed Mar 10, 2021 18:18 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 2,373 | $35.11 | $83,313.42 |
DisclosureSEC source: 0001213900-21-014656 · ownership.xml · nonDerivative · entry 5 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,228 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F5 · price: Sales prices range from $35.00 to $35.37 per share, inclusive. Read SEC document |
| March 09, 2021 Filed Mar 10, 2021 18:18 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 1,800 | $36.02 | $64,836.00 |
DisclosureSEC source: 0001213900-21-014656 · ownership.xml · nonDerivative · entry 4 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,601 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F4 · price: Sales prices range from $36.02 to $36.51 per share, inclusive. Read SEC document |
| March 09, 2021 Filed Mar 10, 2021 18:18 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 5,727 | $35.42 | $202,857.21 |
DisclosureSEC source: 0001213900-21-014656 · ownership.xml · nonDerivative · entry 3 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,401 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F3 · price: Sales prices range from $35.02 to $35.95 per share, inclusive. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 18:18 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionOptions to purchase common stock · Derivative | 10,000 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001213900-21-014656 · ownership.xml · derivative · entry 6 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,350 Underlying: Common Stock · 10,000 shares Expires 2027-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Not applicable F6 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 18:18 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 100 | $35.00 | $3,500.00 |
DisclosureSEC source: 0001213900-21-014656 · ownership.xml · nonDerivative · entry 2 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,128 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 18:18 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionCommon Stock | 10,000 | $3.24 | $32,400.00 |
DisclosureSEC source: 0001213900-21-014656 · ownership.xml · nonDerivative · entry 1 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,228 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 16:48 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionOptions to purchase common stock · Derivative | 3,000 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001213900-21-012169 · ownership.xml · derivative · entry 4 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,250 Underlying: Common Stock · 3,000 shares Expires 2027-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable F5 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 16:48 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 1,400 | $34.67 | $48,544.44 |
DisclosureSEC source: 0001213900-21-012169 · ownership.xml · nonDerivative · entry 3 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,228 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F4 · price: Sales prices range from $34.47 to $35.03 per share, inclusive. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 16:48 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 1,600 | $33.74 | $53,984.80 |
DisclosureSEC source: 0001213900-21-012169 · ownership.xml · nonDerivative · entry 2 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,628 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F3 · price: Sales prices range from $33.35 to $34.30 per share, inclusive. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 16:48 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionCommon Stock | 3,000 | $3.24 | $9,720.00 |
DisclosureSEC source: 0001213900-21-012169 · ownership.xml · nonDerivative · entry 1 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,228 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 17:08 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionOptions to purchase common stock · Derivative | 1,428 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001213900-21-009696 · ownership.xml · derivative · entry 3 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,250 Underlying: Common Stock · 1,428 shares Expires 2027-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Not applicable F4 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 17:08 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 1,428 | $35.39 | $50,542.06 |
DisclosureSEC source: 0001213900-21-009696 · ownership.xml · nonDerivative · entry 2 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,228 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F3 · price: Sales prices range from $35.12 to $35.96 per share, inclusive. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 17:08 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionCommon Stock | 1,428 | $3.24 | $4,626.72 |
DisclosureSEC source: 0001213900-21-009696 · ownership.xml · nonDerivative · entry 1 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2021 Filed Feb 10, 2021 19:25 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 2,410 | $35.20 | $84,825.49 |
DisclosureSEC source: 0001213900-21-008202 · ownership.xml · nonDerivative · entry 4 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,228 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F5 · price: Sales prices range from $35.00 to $35.64 per share, inclusive Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 19:25 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 5,359 | $35.24 | $188,843.12 |
DisclosureSEC source: 0001213900-21-008202 · ownership.xml · nonDerivative · entry 3 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,638 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F4 · price: Sales prices range from $35.00 to $35.82 per share, inclusive Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 19:25 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionOptions to purchase common stock · Derivative | 11,372 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001213900-21-008202 · ownership.xml · derivative · entry 5 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,678 Underlying: Common Stock · 11,372 shares Expires 2027-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Not applicable F6 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 19:25 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 3,603 | $35.04 | $126,241.55 |
DisclosureSEC source: 0001213900-21-008202 · ownership.xml · nonDerivative · entry 2 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,997 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F3 · price: Sales prices range from $35.00 to $35.29 per share, inclusive. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 19:25 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionCommon Stock | 11,372 | $3.24 | $36,845.28 |
DisclosureSEC source: 0001213900-21-008202 · ownership.xml · nonDerivative · entry 1 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 17:38 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 100 | $35.00 | $3,500.00 |
DisclosureSEC source: 0001213900-21-006832 · ownership.xml · nonDerivative · entry 3 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,228 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 17:38 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionOptions to purchase common stock · Derivative | 3,200 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001213900-21-006832 · ownership.xml · derivative · entry 4 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,050 Underlying: Common Stock · 3,200 shares Expires 2027-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Not applicable F4 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 17:38 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 3,100 | $35.04 | $108,633.92 |
DisclosureSEC source: 0001213900-21-006832 · ownership.xml · nonDerivative · entry 2 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,328 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F3 · price: Sales prices range from $35.00 to $35.21 per share, inclusive. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 17:38 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionCommon Stock | 3,200 | $3.24 | $10,368.00 |
DisclosureSEC source: 0001213900-21-006832 · ownership.xml · nonDerivative · entry 1 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 17:24 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionOptions to purchase common stock · Derivative | 3,000 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001213900-21-005451 · ownership.xml · derivative · entry 4 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,250 Underlying: Common Stock · 3,000 shares Expires 2027-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable F5 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 17:24 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 1,200 | $32.43 | $38,916.00 |
DisclosureSEC source: 0001213900-21-005451 · ownership.xml · nonDerivative · entry 3 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,228 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F4 · price: Sales prices range from $32.66 to $33.43 per share, inclusive. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 17:24 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 1,800 | $31.59 | $56,862.00 |
DisclosureSEC source: 0001213900-21-005451 · ownership.xml · nonDerivative · entry 2 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,428 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F3 · price: Sales prices range from $31.59 to $32.50 per share, inclusive. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 17:24 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionCommon Stock | 3,000 | $3.24 | $9,720.00 |
DisclosureSEC source: 0001213900-21-005451 · ownership.xml · nonDerivative · entry 1 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,228 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.